NEW YORK ( TheStreet) -- Biotech, biotech, biotech. That's been the talk of Wall Street for all of 2013, with mergers and acquisitions happening every other day. That's why TheStreet's Jim Cramer and "Mad Money" Research Director Nicole Urken discussed which biotechs could be the next to merge.
Cramer still expects a company to bid for Alexion Pharmaceuticals (ALXN).
He added that while there are a lot of IPOs coming to the market, he continues to like the "four horsemen," of which he means Celgene (CELG - Get Report), Regeneron Pharmaceuticals (REGN - Get Report), Gilead Sciences (GILD - Get Report), and Biogen (BIIB - Get Report).Biotech has been hot for several reason, Urken said, citing an improved Food and Drug Administration process, a more risk-absorbing investor base and a stronger pipeline of products. Also, these companies continue to grow at strong rates without the macro headwinds slowing them down. Specifically, Cramer said there's one company in the sector he really loves: Celgene. The company has a ton of products in its pipeline and is actually cheap when looking at it on a valuation basis. He also said Gilead Sciences could be a good company to look at it if its hepatitis-C drug pans out the way some are expecting. -- Written by Bret Kenwell in Petoskey, Mich. Follow @BretKenwell
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts